PTO/SB/08a (08-03) Approved for use through 07/31/2006, OMB 0651-0031

ark Office: ILS DEPARTMENT OF COMMERCE

Under the	Paperwork l	Reduction Act of 1995, no persons are required to	respond to a			l number.		
Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT				Complete if Known				
				Application Number	10/649,873			
				Filing Date	August 28, 2003			
				First Named Inventor	PELED Amnon et al			
31	A LISIV	IEMI DI AITLICANI	Group Art Unit					
	(use as	many sheets as necessary)	Examiner Name					
Sheet		2 Of	3	Attorney Docket Number	26732			
OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS								
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial symposium, catalog, etc.) date, page(s), volume-issue number(s), publisher, city, and/or country where published.						
/BH/	1	Baggiolini et al. "CC Chemokines in Allergic Inflammation", Immunology Today, 15(3): 127-133, 1994.						
/BH/	2	Cocchi et al. "Identification of RANTES, MIP-1α, and MIP-1β as the Major HIV- Suppressive Factors Produced by CD8+ T Cells", Science, 270: 1811-1815, 1995.						
/BH/	3	Ma et al. "Impaired B-Lymphopoiesis, Myclopolesis, and Derailed Cerebellar Neuron Migration in CXCR4- and SDF-1-Deficient Mice", Proc. Natl. Acad. Sci. USA, 95; 9448-943, 1998.						
/BH/	4	Müller et al. "Involvement of Chemokine Receptors in Breast Cancer Metastasis", Nature, 410: 50-56, 2001.						
/BH/	5	Stricter et al. "The Functional Role of the ELR Motif in CXC Chemokine-Mediated Angiogenesis", The Journal of Biological Chemistry, 270(45): 27348-27357, 1995.						
/BH/	6	Vaddi et al. "Regulation of Monocyte Integrin Expression by β-Family Chemokines", The Journal of Immunology, 153: 4721-4732, 1994.						
	-							

Examiner Signature	/Bruce Hissong/	Date Considered	09/28/2008

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. include copy of copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional).

<sup>2</sup> See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901 04.3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3).

For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document.

<sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST, 16 if possible.

<sup>&</sup>lt;sup>6</sup> Applicant is to place a check mark here if English language translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14, this collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of commerce, P.O. Box 1450, Alexandria, VA 22313-1450 DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450